Vmy 1-103 manufacturers
- VMY-1-103
-
- $2500.00
-
2026-07-27
- CAS:1209002-43-6
- Purity:
- Supply Ability: 10g
|
| | Vmy 1-103 Basic information |
| Product Name: | Vmy 1-103 | | Synonyms: | 2-chloro-N-[2-[[5-(dimethylamino)naphthalen-1-yl]sulfonylamino]ethyl]-4-[[2-[[(2R)-1-hydroxy-3-methylbutan-2-yl]amino]-9-propan-2-ylpurin-6-yl]amino]benzamide;Benzamide, 2-chloro-N-[2-[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]amino]ethyl]-4-[[2-[[(1R)-1-(hydroxymethyl)-2-methylpropyl]amino]-9-(1-methylethyl)-9H-purin-6-yl]amino]-;2-chloro-N-{2-[5-(dimethylamino)naphthalene-1-sulfonamido]ethyl}-4-[(2-{[(2R)-1-hydroxy-3-methylbutan-2-yl]amino}-9-(propan-2-yl)-9H-purin-6-yl)amino]benzamide;Vmy 1-103 | | CAS: | 1209002-43-6 | | MF: | C34H42ClN9O4S | | MW: | 708.27 | | EINECS: | | | Product Categories: | | | Mol File: | 1209002-43-6.mol |  |
| | Vmy 1-103 Chemical Properties |
| density | 1.39±0.1 g/cm3(Predicted) | | pka | 10.91±0.50(Predicted) |
| | Vmy 1-103 Usage And Synthesis |
| Description | VMY-1-103 is a potent CDK inhibitor, is also a novel dansylated analog of purvalanol B, was shown to inhibit cell cycle progression and proliferation in prostate and breast cancer cells more effectively than purvalanol B. VMY-1-103 , but not purvalanol B, significantly decreased the proportion of cells in S phase and increased the proportion of cells in G(2)/M. VMY-1-103 increased the sub G(1) fraction of apoptotic cells, induced PARP and caspase-3 cleavage and increased the levels of the Death Receptors DR4 and DR5, Bax and Bad while decreasing the number of viable cells, all supporting apoptosis as a mechanism of cell death. VMY-1-103 possesses unique antiproliferative capabilities and that this compound may form the basis of a new candidate drug to treat medulloblastoma. | | Uses | VMY-1-103 is an inhibitor for cyclin/Cdk complex, that arrests the cell cycle at G1 phase. VMY-1-103 reduces mitochondrial membrane potential, induces p53 phosphorylation and and PARP cleavage, activates caspase-3, and thus induces apoptosis in prostate cancer cell LNCaP[1]. | | References | [1] Ringer L, et al., VMY-1-103, a dansylated analog of purvalanol B, induces caspase-3-dependent apoptosis in LNCaP prostate cancer cells. Cancer Biol Ther. 2010 Aug 15;10(4):320-5. DOI:10.4161/cbt.10.4.12208 |
| | Vmy 1-103 Preparation Products And Raw materials |
|